Values First Advisors’s Trillium Therapeutics Inc. TRIL Stock Holding History

Values First Advisors’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-25,768	Closed	-$452K	–	177
2021 Q3	$452K	Buy	25,768 +6,620	+35%	+$77.3K	0.29%	100
2021 Q2	$186K	Buy	19,148 +6,103	+47%	+$57.4K	0.13%	140
2021 Q1	$140K	Buy	+13,045	New	+$161K	0.1%	136

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Values First Advisors's TRIL Position: Q4 2021 in Review

Values First Advisors sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 25,768 shares — an estimated $452K sold.

Values First Advisors first reported a position in TRIL in Q1 2021 and held it in 3 quarters. The position peaked at $452K in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Values First Advisors reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Values First Advisors sold 25,768 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $452K.
Values First Advisors first reported a position in Trillium Therapeutics Inc. in Q1 2021 and held it in 3 quarters.
Values First Advisors's Trillium Therapeutics Inc. position peaked at $452K in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Values First Advisors's 13F filing for Q4 2021, filed 10 Mar 2022.